For these reasons, clinically used anti-hypertensive mainstay therapies that provide reno-protection and reduce the risk of progression to end-stage renal disease including angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) were developed (Wenzel, 2005). Here, ACE is linked to stage 5 chronic kidney disease.